Psoriatic Arthritis
VIDEO: Diagnostic challenges in psoriatic arthritis
Ethan Craig, MD, spoke with Healio about diagnostic challenges in psoriatic arthritis.
FDA approves higher-dose Bimzelx prefilled syringes, autoinjectors
The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.
Imuldosa snags FDA approval as fifth Stelara biosimilar in mounting market logjam
The FDA has approved the Stelara biosimilar, Imuldosa, for Crohn’s disease, ulcerative colitis and all other indications of the reference product, and the latest addition to the Stelara biosimilar bottleneck set to release in 2025.
Apremilast improves pain, disease activity in early oligoarticular psoriatic arthritis
Treatment with apremilast led to improved clinical and patient-reported outcomes in early oligoarticular psoriatic arthritis at 16 weeks, according to data published in Annals of the Rheumatic Diseases.
Dual therapy can have ‘synergistic effect’ in difficult-to-treat inflammatory diseases
SAN DIEGO — Certain dual therapy strategies, including interleukin-17 plus IL-23 inhibition, or Janus kinase inhibitors alongside TNF inhibitors, can be effective for difficult-to-treat inflammatory diseases, according to a speaker here.
‘It’s going to be ubiquitous’: Weight loss drugs may aid rheumatic disease treatment
SAN DIEGO — GLP-1 agonists and other drugs that have recently made headlines for their weight loss applications will be useful in helping patients meet goals in psoriatic arthritis and other rheumatic diseases, according to a speaker here.
'Better imaging' can improve understanding of inflammatory arthritis
SAN DIEGO — New imaging technologies, and improved use of the ones currently available, may move rheumatology closer to precision medicine in inflammatory arthritis, according to a speaker at the 2024 Congress of Clinical Rheumatology West.
Healio Minute Podcast, Rheumatology/Psoriatic Arthritis Edition: Top Headlines - Week of September 23, 2024
In this edition, blue-collar workers more likely to miss work or quit due to psoriatic arthritis, infliximab biosimilar increase after release of a third option and more.
Substance use disorder predicts long-term opioid use in psoriatic arthritis, axial SpA
Smoking, substance use disorder and taking gabapentinoids or antidepressants predict long-term opioid use among patients with axial spondyloarthritis and psoriatic arthritis, according to data published in Rheumatology.
Psoriatic arthritis activity measured via DAPSA28 ‘highly analogous’ to DAPSA gold standard
The 28-joint Disease Activity Index for Psoriatic Arthritis score is superior to the DAS28-CRP score as a measure of disease activity in PsA if the “gold standard” DAPSA 66/68 joint counts are not available, according to data.